logo-loader
viewMaxCyte Inc

MaxCyte deal with Caribou 'demonstrates expertise and value' of its Flow Electroporation technology

Proactive Research analyst Emma Ulker discusses MaxCyte’s (LON:MXCT) new clinical and commercial licence agreement with Caribou Biosciences.

She says the agreement which allows the use of its proprietary Flow Electroporation technology for Caribou’s CRISPR gene-edited allogeneic T-cell therapy programmes is the latest in a series of late-stage clinical and commercial collaborations in cell and gene therapy.

Click here to read Emma Ulker's latest update on Maxcyte

Quick facts: MaxCyte Inc

Price: 177 GBX

AIM:MXCT
Market: AIM
Market Cap: £135.56 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of MaxCyte Inc named herein, including the promotion by the Company of MaxCyte Inc in any Content on the Site, the Company receives from said...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Maxcyte deal with Allogene Therapeutics 'a clear endorsement' of its technology

Proactive Research analyst Emma Ulker says MaxCyte’s (LON:MXCT) deal with clinical-stage industry leader Allogene Therapeutics (NASDAQ:ALLO) is a clear endorsement of the features of its Flow Electroporation technology. Described by Allogene as the ‘industry standard’, MXCT’s Flow...

on 26/3/20

2 min read